Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.61 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | F11 | P03951 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952504 | 0.86 | LPL (0.65) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL18762839 | 0.82 | HRH3 (0.84) | HRH3TAAR1 | |
| SCHEMBL890400 | 0.79 | LPL (0.73) | LPLLIPGCA2CA1TRPV1 | |
| SCHEMBL4737133 | 0.79 | LPL (0.55) | LPLLIPGHRH3CA2CA1 | |
| SCHEMBL2386907 | 0.78 | LPL (0.58) | LPLLIPGHRH3CA2CA1 | |
| Hydrochloric Acid SCHEMBL3109951 | 0.77 | LPL (0.56) | LPLLIPGHRH3CA2CA1 | |
| Hydrochloric Acid SCHEMBL3330626 | 0.76 | SIGMAR1 (0.53) | LPLLIPGCA2CA1TAAR1 | |
| SCHEMBL257735 | 0.76 | LPL (1.00) | LPLLIPGCA2CA1TRPV1 | |
| Hordenine SCHEMBL19896488 | 0.76 | HRH3 (0.67) | HRH3CA2TAAR1 | |
| Hordenine SCHEMBL36798 | 0.76 | HRH3 (0.67) | HRH3CA2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885HRH3 40/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | LPL 3972/4885LIPG 3859/4885HRH3 1270/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | LPL 2221/4885LIPG 2618/4885HRH3 40/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | LPL 1131/4885LIPG 1319/4885HRH3 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.